Zaki Molvi
Affiliations: | Physiology, Biophysics and Systems Biology | Weill Cornell Medical College, New York, NY, United States | |
| Immunology | Sloan Kettering Institute, New York, NY, United States |
Google:
"Zaki Molvi"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Young Jik Kwon | research assistant | 2013-2017 | UC Irvine |
| Richard J. O'Reilly | grad student | 2018- | Sloan Kettering Institute (Cell & Gene Therapy Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Molvi Z, Klatt MG, Dao T, et al. (2023) The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Journal For Immunotherapy of Cancer. 11 |
| Malviya M, Aretz ZEH, Molvi Z, et al. (2023) Challenges and solutions for therapeutic TCR-based agents. Immunological Reviews |
| Molvi Z, Klatt MG, Dao T, et al. (2023) The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Biorxiv : the Preprint Server For Biology |
| O'Reilly RJ, Molvi Z. (2022) CMV-specific T-cells following haploidentical transplants: reshaping a repertoire by half. Haematologica |
| Gigoux M, Holmström MO, Zappasodi R, et al. (2022) Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine. 14: eaba4380 |
| Bourne CM, Mun SS, Dao T, et al. (2022) Unmasking the suppressed immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas with combination drug treatment. Blood Advances |
| Molvi Z, O'Reilly RJ. (2022) Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer. Cancer Treatment and Research. 183: 131-159 |
| Dao T, Mun SS, Molvi Z, et al. (2022) A TCR mimic monoclonal antibody reactive with the "public" phospho-neoantigen pIRS2/HLA-A*02:01 complex. Jci Insight. 7 |
| Jones HF, Molvi Z, Klatt MG, et al. (2021) Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. Frontiers in Immunology. 11: 585385 |
| Deh K, Ponath GD, Molvi Z, et al. (2018) Magnetic susceptibility increases as diamagnetic molecules breakdown: Myelin digestion during multiple sclerosis lesion formation contributes to increase on QSM Journal of Magnetic Resonance Imaging |